Metro-Minnesota Community Oncology Research Consortium

Recent papers from Metro-Minnesota Community Oncology Research Consortium

1. Changes in Alcohol Use Among Adults with Cancer Participating in the ECOG-ACRIN EAQ171CD Tobacco Treatment TrialCancer Epidemiology Biomarkers & Prevention · 2026
2. Extrusion of Temporary Pacing Wire From Prior Cardiac Surgery During Routine Excision of a Suspected CystDermatologic Surgery · 2026
3. Virtual Sustained Tobacco Treatment for Patients With Cancer: A Randomized Controlled Trial (ECOG-ACRIN: EAQ171CD) Within the National Cancer Institute Community Oncology Research ProgramJournal of Clinical Oncology · 2026
4. Communication With Older Patients With Cancer Using Geriatric Assessment: A Cluster-Randomized Clinical Trial From the National Cancer Institute Community Oncology Research Program2019
5. Post-hoc efficacy and biomarker analysis of elraglusib plus gemcitabine/nab-paclitaxel versus chemotherapy alone in metastatic pancreatic ductal adenocarcinoma.Journal of Clinical Oncology · 2026
6. Impact of Race, Socioeconomic Status, and Clinicopathologic Features on Clinical Outcomes in Triple-Negative Breast Cancer in the ECOG-ACRIN EA1131 TrialJCO oncology advances. · 2026
7. Elraglusib and chemotherapy in metastatic pancreatic ductal adenocarcinoma: a randomized controlled phase 2 trialNature Medicine · 2026
8. Effects of Exercise on Cognitive Impairment in Patients Receiving Chemotherapy: A Multicenter Phase III Randomized Controlled TrialJournal of the National Comprehensive Cancer Network · 2026
9. Antiretroviral therapy switch among Medicare beneficiaries with HIVJournal of Managed Care & Specialty Pharmacy · 2026
10. Abstract RF7-07: Adjuvant Palbociclib for ER+ Breast Cancer in the PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): Post-Recurrence Treatment and Overall SurvivalClinical Cancer Research · 2026
11. Abstract PD1-09: Nausea as a Mediator of Olanzapine’s effect on Quality-of-Life Improvement in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Insights from a Phase III NCORP RCTClinical Cancer Research · 2026
12. Abstract RF3-06: Tumor infiltrating lymphocytes in post-NACT residual tumors in ECOG-ACRIN EA1131 - impact of intrinsic subtypesClinical Cancer Research · 2026
13. Work Ability in Young Adult Survivors (WAYS WF-10217): Documenting Labor Force Participation, Occupation, and Educational Attainment Following Cancer TreatmentJournal of Adolescent and Young Adult Oncology · 2026
14. Results from the randomized phase 2 study (1801 Part 3B) of elraglusib plus gemcitabine/nab-paclitaxel (GnP) versus GnP in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).Journal of Clinical Oncology · 2026
15. A First-In-Human Study of the SUMOylation Inhibitor Subasumstat in Patients with Advanced/Metastatic Solid Tumors or Relapsed/Refractory Hematologic MalignanciesCancer Research Communications · 2025
16. Dual Immune Check Point Blockade in2025
17. Impact of Drug Shortages on Cancer Care Delivery Within the National Cancer Institute Community Oncology Research ProgramJCO Oncology Practice · 2025
18. The Effectiveness of Transcranial Magnetic Stimulation in Adolescents and Young Adults With Major Depressive DisorderJAACAP Open · 2025
19. Final report on North Central Cancer Treatment Group N0877 (alliance): A phase II randomized, placebo-controlled trial of chemoradiotherapy with or without dasatinib for glioblastomaNeuro-Oncology · 2025
20. Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive‐stage small cell lung cancer (ES‐SCLC): ECOG‐ACRIN EA5161Cancer · 2025